(Core 1) This proposal brings together the translational medicine and research expertise of Dana-Farber Cancer Institute (DFCI), Dana Farber/Harvard Cancer Center, and Massachusetts Institute of Technology (MIT) with the clinical research strength of Intergroupe Francophone du Myeloma (IFM) in France and the genomics expertise of the Sanger Institute in the UK to develop a curative strategy for MM. In this international collaborative renewal application, we now propose to build on our highly successful genomic, preclinical, clinical, and administrative strengths to address the next generation of questions that will ultimately lead to therapeutic advances for cure. Most importantly, our current study has confirmed that achieving MRD negative status provides significantly superior survival outcome. In this proposal, we will now undertake an international collaborative trial to address the next most important issue of how MRD status will inform our therapeutic decision algorithm (Project 1). Importantly, the large number of uniformly treated patients will allow us to both identify genomic and epigenomic correlates of disease behavior (Project 2) and identify molecular circuits and validate novel combination targeted therapeutic approaches (Project 3) as well as to define the mechanisms and clinical implications of genomic instability in MM (Project 4). This unique international collaborative effort requires significant co-ordination of effort, integration of strategies, monitoring and oversight of various functions, and communication between investigators at various dispersed sites. The key function of Core A is integration of the research efforts and communication between investigators. Scientific and administrative integration is essential to assure successful interaction between the four Projects, as well as between the laboratory and clinical components within and between projects in this multinational multi-institutional program. Therefore, this central core will provide the link between various projects and successfully co-ordinate the clinical study and the proposed correlative science. To aid in achieving these goals, Core A will: monitor the timely conduct of the clinical study and assure progress in tissue collection, processing and usage to co- ordinate interaction between the clinical and correlative science studies (Specific Aim 1); co-ordinate communication, and exchange of data between investigators at various international sites (Specific Aim 2); provide necessary resources, fiscal oversight and administrative support for projects and cores (Specific Aim 3); facilitate intra-programatic interactions, meetings, travel and Internal and External Advisory Committees (Specific Aim 4).

Public Health Relevance

(Core 1) The core will provide a central integrative function monitoring conduct of international clinical trial and sample collection and processing, providing effective communication between investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA155258-06
Application #
9209425
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2011-12-01
Project End
2022-07-31
Budget Start
2017-03-15
Budget End
2018-02-28
Support Year
6
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Fulciniti, Mariateresa; Martinez-Lopez, Joaquin; Senapedis, William et al. (2017) Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood 129:2233-2245
Magrangeas, Florence; Kuiper, Rowan; Avet-Loiseau, Hervé et al. (2016) A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clin Cancer Res 22:4350-4355
Ohguchi, Hiroto; Hideshima, Teru; Bhasin, Manoj K et al. (2016) The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun 7:10258
Stroopinsky, Dina; Kufe, Donald; Avigan, David (2016) MUC1 in hematological malignancies. Leuk Lymphoma 57:2489-98
Richardson, Paul G; Hungria, Vânia T M; Yoon, Sung-Soo et al. (2016) Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood 127:713-21
Fulciniti, M; Amodio, N; Bandi, R L et al. (2016) miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J 6:e380
Szalat, Raphael; Avet-Loiseau, Herve; Munshi, Nikhil C (2016) Gene Expression Profiles in Myeloma: Ready for the Real World? Clin Cancer Res 22:5434-5442
Amodio, Nicola; Stamato, Maria Angelica; Gullà, Anna Maria et al. (2016) Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Mol Cancer Ther 15:1364-75
Xu, Lian; Hunter, Zachary R; Tsakmaklis, Nicholas et al. (2016) Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol 172:735-44
Gullà, Annamaria; Di Martino, Maria Teresa; Gallo Cantafio, Maria Eugenia et al. (2016) A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res 22:1222-33

Showing the most recent 10 out of 180 publications